In diltiazem‑resistant paroxysmal supraventricular tachycardia (PSVT), what is the drug of choice?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Drug of Choice for Diltiazem-Resistant PSVT

In diltiazem-resistant PSVT, intravenous beta-blockers (esmolol, metoprolol, or propranolol) are the drug of choice for hemodynamically stable patients. 1

Rationale and Treatment Algorithm

When diltiazem fails to terminate PSVT, the treatment approach depends on hemodynamic stability:

For Hemodynamically Stable Patients:

Intravenous beta-blockers are recommended as the next-line agent after calcium channel blocker failure. The 2015 ACC/AHA/HRS guidelines specifically recommend IV beta-blockers (esmolol, metoprolol, or propranolol) as reasonable alternatives for acute treatment of AVNRT when initial therapy fails 1.

  • Esmolol: 500 mcg/kg IV bolus over 1 minute, followed by infusion at 50-300 mcg/kg/min
  • Metoprolol: 2.5-5 mg IV bolus over 2 minutes, can repeat up to 3 doses
  • Propranolol: 1 mg IV over 1 minute, can repeat at 2-minute intervals up to 3 doses 1

For Hemodynamically Unstable Patients:

Synchronized cardioversion is mandatory when pharmacological therapy fails or is not feasible 1. This is highly effective in terminating SVT and should not be delayed in unstable patients.

Alternative Pharmacological Option:

Intravenous verapamil can be considered if beta-blockers are contraindicated, as it represents the other calcium channel blocker class with different pharmacokinetics than diltiazem 1. However, if diltiazem failed, verapamil may also be ineffective since both are non-dihydropyridine calcium channel blockers with similar mechanisms.

Intravenous amiodarone may be considered as a last-resort pharmacological option before cardioversion 1, though it has been downgraded in recent guidelines 2.

Important Caveats:

  • Do not use verapamil or any calcium channel blocker if pre-excited atrial fibrillation/flutter or WPW syndrome is present, as this can precipitate ventricular fibrillation 1
  • Avoid beta-blockers in patients with decompensated heart failure, severe reactive airway disease, or cardiogenic shock 1
  • Beta-blockers have an excellent safety profile but may be less effective than calcium channel blockers for acute termination (one trial showed diltiazem superior to esmolol) 1
  • The 2019 ESC guidelines downgraded both verapamil and diltiazem for acute management of narrow-QRS tachycardias, while adenosine remains the initial drug of choice 2

Transition Strategy:

After acute termination, the FDA label indicates that transition to other antiarrhythmic agents is generally safe within 3 hours, including oral digoxin, Class I antiarrhythmics, calcium channel blockers, or oral beta-blockers 3.

References

Related Questions

What is the appropriate management of paroxysmal supraventricular tachycardia (PSVT) in a patient who is post‑percutaneous transluminal coronary angioplasty (PTCA) with stent placement and on dual antiplatelet therapy?
Which drugs can precipitate paroxysmal supraventricular tachycardia (PSVT) and what are the recommended acute and long‑term treatment options?
In a 50-year-old patient with paroxysmal supraventricular tachycardia at 180 bpm, what should be done?
What is the ideal β‑blocker for long‑term oral management of supraventricular tachycardia in a patient with low normal blood pressure?
In a patient with recurrent paroxysmal supraventricular tachycardia, what preventive medications and investigations are recommended?
What are the indications, dosing regimen, contraindications, monitoring requirements, and common adverse effects of voglibose in adults with type 2 diabetes?
In a patient with recurrent exercise‑induced rhabdomyolysis who has undergone comprehensive next‑generation sequencing panels (rhabdomyolysis and metabolic myopathy, glycogen storage diseases, fatty‑acid oxidation defects, neuromuscular super panel, and other rare neuromuscular disorders), what is the appropriate next step in management while awaiting the genetic report?
What is the role of pyridoxine (vitamin B6) in the treatment of primary hyperoxaluria type 1?
In a child with persistent high fever, tachycardia, tachypnea, and mild splenomegaly but a negative malaria parasite test, how should severe malaria be managed?
Should I diagnose female pattern hair loss without hormonal labs and start treatment with topical or oral minoxidil, PRP, or off‑label anti‑androgens in a woman (adolescent or post‑menopausal) who has no signs of hyperandrogenism or family history?
What are the current guidelines for the diagnosis and management of malaria, including treatment regimens, dosing, and supportive care?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.